• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acute Heart Failure - Pipeline Review, Q1 2011 - Product Image

Acute Heart Failure - Pipeline Review, Q1 2011

  • ID: 1574103
  • February 2011
  • 29 pages
  • Global Markets Direct

Acute Heart Failure - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Acute Heart Failure - Pipeline Review, Q1 2011', provides an overview of the Acute Heart Failure therapeutic pipeline. This report provides information on the therapeutic development for Acute Heart Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Heart Failure. 'Acute Heart Failure - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Heart Failure.
- A review of the Acute Heart Failure products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Heart Failure Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Heart Failure
Acute Heart Failure Therapeutics under Development by Companies
Acute Heart Failure Therapeutics under Investigation by Universities/Institutes
Companies Involved in Acute Heart Failure Therapeutics Development
Novartis AG
Bayer AG
Nile Therapeutics, Inc.
Trevena, Inc.
Cardiokine, Inc.
Cardioxyl Pharmaceuticals, Inc.
Pharis Biotec GmbH
Universities/Institutes Involved in Acute Heart Failure Therapeutics Development
Acute Heart Failure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Lixivaptan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relaxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Acute Heart Failure - Featured News
1. Nov 02, 2010: Nile Therapeutics Phase II Study Of CD-NP In Acute Decompensated Heart Failure Meets Primary Endpoint
2. Jul 16, 2008: URGENT Study Provides Important New Insight Into The Use Of Dyspnea As A Clinical Endpoint For Evaluating New Treatments For Acute Heart Failure Syndromes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Heart Failure, 2011
Products under Development for Acute Heart Failure – Comparative Analysis, 2011
Novartis AG, 2011
Bayer AG, 2011
Nile Therapeutics, Inc., 2011
Trevena, Inc., 2011
Cardiokine, Inc., 2011
Cardioxyl Pharmaceuticals, Inc., 2011
Pharis Biotec GmbH, 2011
Assessment by Monotherapy Products, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Acute Heart Failure, 2011
Products under Development for Acute Heart Failure – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Assessment by Monotherapy Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos